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Summary
Objective: A double-blind, placebo-controlled dose-finding study was performed in 237 patients with predominantly unilateral knee
osteoarthritis (OA) evaluating efficacy and safety of a new topical NSAID.
Design: The patients applied 3 g tid eltenac gel 0.1%, 0.3%, 1% or placebo gel over a period of 4 weeks. The patients were supplied with
paracetamol tablets as an escape analgesic.
Primary efficacy end-point was mean global pain in the week preceding the examinations, evaluated on a visual analog scale (VAS).
Secondary criteria were Lequesne’s score ISK, Jezek score, muscle strength and dolorimeter measurements, walking time, clinical
examination results of the knee joint and patient’s and investigator’s overall efficacy estimates.
Results: The graphical depiction of VAS and ISK suggested a dose-related efficacy, but the pre-planned statistical analysis did not show
significant differences between treatments.
In the patient subgroup with a higher degree of baseline severity of knee OA the ISK showed significant and relevant advantages of eltenac
gel 1% to placebo at different examination times.
Two patients each of the eltenac gel 1% group and the placebo group showed local intolerance reactions which subsided spontaneously.
Conclusion: This study did not provide confirmatory proof of an efficacy of topical eltenac in patients with knee OA. Methodological pitfalls
and possible responder subgroups are described. Despite the difficulties, dose-finding studies seem to be feasible even with topical NSAIDs.
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Osteoarthritis (OA) of the knee joint is the most common
joint disorder, increasing in prevalence with age and a
continuously higher life expectancy1–3.
In OA oral non-steroidal antiinflammatory drugs
(NSAIDs) are used for the temporary relief of symptoms.
They show a marked influence on inflammatory signs and
on joint pain in OA and also on the functional impairment
typical for the disease. These effects can be explained by
the analgesic and/or antiphlogistic properties of those
drugs. As articular cartilage does not have any pain recep-
tors, a periarticular and capsular origin of pain seems
probable, although the exact mechanism is not clear.
Because of their unfavorable side effect profile, an
alternative to the oral administration of NSAIDs is desirable273despite their clinical efficacy. The adverse drug reactions to
NSAIDs given systemically include gastro-intestinal distur-
bances in 25–50% of the treated patients as well as CNS
disorders and influences on hematopoiesis and hepatic
and renal function4.
As these adverse drug effects are dose-dependent,
the reduction of NSAID plasma levels seems promising,
if sufficiently high concentrations in the target tissues
(muscles, tendons, fasciae, joint capsule, possibly sensory
nerves) can be reached. Thus the topical application of
NSAIDs with a sufficiently high percutaneous penetration
may offer an improvement of the benefit–risk ratio in
patients with knee OA and a periarticular involvement.
The topical NSAID used in this study, eltenac, is a
compound with a structural similarity to diclofenac, with
one benzene ring being substituted by a thiophen ring.
Pre-clinical and clinical experiments suggest that this
modification improves absorption after topical application
and binding to inflamed tissues5.
Eltenac is a cyclo-oxygenase inhibitor and thus reduces
the synthesis of prostaglandins, which have a role in the
transmission of pain. On a weight or concentration basis,
eltenac is approximately twice as active as diclofenac.
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DESIGN
A placebo-controlled, randomized and double-blind
study was performed through four centers (National
Institute for Rheumatology and Physiotherapy in Budapest,
Hungary; National Institute for Rheumatology in Prague,
Czech Republic; Department of Rheumatology and
Institute for Physical Therapy in Zurich, Switzerland;
orthopedic practice in Landshut, Germany).
The study investigated the usefulness of different con-
centrations of eltenac gel in patients with knee OA. It
compared eltenac gel 0.1%, eltenac gel 0.3% and eltenac
gel 1% over a 4-week treatment period with a correspond-
ing placebo gel (gel base of eltenac), which could not be
distinguished from the active preparations.PATIENTS
Male and female patients with primary, manifest, uni-
lateral painful knee OA were selected for this study. Knee
OA was diagnosed according to the validated criteria of the
American College of Rheumatology: moderate/medium
degree of pain in the knee for most days of the previous
month; femoro-tibial osteophytes in the X-ray; one or more
of the following three additional criteria: age >50 years,
morning stiffness for less than 30 min and crepitation on
active movement7.
Patients had to experience tenderness on pressure of
the periarticular tissue or muscular insertions at the admis-
sion examination. Throughout the study they also had
to avoid concomitant therapy such as physiotherapy
(apart from isometric quadriceps training), intraarticular
punctures/injections, symptomatic slow-acting drugs in OA,
additional analgesics or antiphlogistics, occlusive dressings
and corticosteroids.
Patients with secondary forms of OA were excluded as
well as patients with primarily inflammatory joint diseases
such as rheumatoid arthritis (RA). If intraarticular drugs or
so-called chondroprotective agents had been administered
within the previous 3 months, patients could not be
included in the study. Patients with symptomatic hip OA
were excluded to avoid any influence on the efficacy
parameters.
For safety reasons patients with contraindications to
NSAIDs and to paracetamol were excluded.
If not already menopausal, female patients had to be on
reliable contraceptive measures (surgical, IUD, hormones).
Pregnant or breast-feeding women could not be entered
into the study.
Patients were only included if they had provided written
informed consent to a study participation.STUDY SCHEDULE
To eliminate carry-over effects of any previous OA
therapy, all patients underwent a 1 week wash-out periodafter inclusion in the study (visit E0). Only the intake of
paracetamol tablets was allowed (up to 4 × 500 mg). Dur-
ing the subsequent treatment period of 4 weeks, weekly
examinations were performed. One further visit was sched-
uled 2 weeks after the end of the treatment period. This
was to allow an estimate of the duration of the treatment
effects and also to allow a follow-up of any adverse events
during the treatment period. Safety laboratory evaluations
were performed at the inclusion in the study and at the end
of treatment.STUDY MEDICATION
Each patient received one 100 g tube eltenac gel 1%,
eltenac gel 0.3%, eltenac gel 0.1% or placebo gel (gel
base)* after each of the examinations E1, E2, E3 and
E4. The gel base was a transparent polyacrylic acid gel
containing 2-propanol, but no penetration enhancer.
The patients were asked to apply approximately 3 g of
the gel [a string approximately 10 cm (4 in) long] to their
knee joint three times daily and to rub the gel into the skin.
The chosen amount corresponds to daily eltenac doses of
90 mg (1% gel), 27 mg (0.3% gel) and 9 mg (0.1% gel).
Patients were supplied with paracetamol 500 mg tablets
(Dignocetamol®†), with the direction not to take more than
four tablets daily in the case of knee pain despite the
application of the study medication. The investigators
asked the patients to use paracetamol restrictively.ASSIGNMENT OF PATIENTS TO TREATMENT AND BLINDING
The patients were assigned to the four treatment groups
‘Eltenac gel 0.1%’, ‘Eltenac gel 0.3%’, ‘Eltenac gel 1%’ and
‘Placebo gel (gel base)’ according to a random plan. This
was generated a priori by the Biometrics Department of
Sankyo Pharma using the method of permuted blocks
(PROC PLAN, SAS® Version 6.08). Block size was 4,
which was not known to the investigators.
Double-blind conditions could be maintained because
eltenac gel and the gel base were indistinguishable in
appearance, handling or labeling. Labeling included the
patient number, a common batch number for all four groups
and no identification of the actual treatment group. Nobody
involved in the performance of the study had access to the
code. It was opened for the statistical evaluation only after
all missing or doubtful data in the case report forms had
been clarified and after a decision had been made as to
whether a patient was to be included in the intention-to-
treat or in the per-protocol analysis.EFFICACY END-POINTS—PRIMARY END-POINT
Primary end-point of this study was the intensity of global
pain in the treated knee joint in the week prior to the
examination. The patient marked a non-divided horizontal
10 cm scale (visual analog pain scale), the ends of which
were described with ‘none’ and ‘unbearable’; these words
were translated into the patients’ native languages.Eltenac is an inhibitor of both cyclo-oxygenase-1 and -2
and is about 3.5 times more selective for cyclo-
oxygenase-2 than diclofenac6.
At the time of the planning of this study, eltenac gel had
shown clinical efficacy in a pilot study in patients with ankle
sprains5.*Eltenac substance produced and supplied by Byk Gulden,
Konstanz, Germany. Eltenac gel and placebo gel produced and
supplied by Luitpold Pharma GmbH, Munich, Germany; now
Sankyo Pharma GmbH.
†Dignocetamol® produced and supplied by Luitpold Pharma
GmbH, Munich, Germany; now Sankyo Pharma GmbH.
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The following secondary end-points were evaluated:
• Index of Severity for the Knee (ISK) according to
Lequesne8. This validated index quantifies the severity of
pain and functional complaints. It was translated into the
patients’ native languages and used as an observer-
assigned instrument.
• The Jezek score is a common observer-assigned instru-
ment in Eastern Europe used for the evaluation of pain in
knee OA9. It has not been validated up to now. It
assesses the items pain on walking, pain when starting to
walk, pain on climbing up the stairs, pain on going down
the stairs, pain at night, pain on maximum flexion and
pain on palpation. Each item is rated from 0 (no pain) to
4 (unbearable pain). This index also was translated into
the patients’ native languages.
• Clinical examination results were recorded for tender-
ness on pressure of the medial and the lateral joint
space, feeling of warmth above the joint, crepitation,
effusion and the range of movement in the knee joint.
• Investigator and patient gave their subjective overall
opinion on the treatment success, using a verbal rating
scale. The words on the patients’ scale were translated
into the patients’ native languages.
• The patients were asked to walk a straight horizontal
indoor distance of 20 m (65 ft) as quickly as possible,
starting from a standing position. The required time was
measured, the use of walking sticks or crutches was
permitted, but had to be documented.
• The strength of the knee flexor and extensor muscles
(knees in 90° flexion) during isometric performance was
evaluated using a Chatillon Dial Push-Pull Gauge DPPH
(John Chatillon & Sons, Inc, Greensboro, NC, U.S.A.).
The maximum force was documented in Newton (N).
• The centers where the use of a dolorimeter was already
established practice in the examination of patients with
knee OA (Budapest, Zurich) also evaluated this par-
ameter. The device was applied to the medial and the
lateral joint space of both knees. The pain threshold was
documented in Newton (N).SAFETY ENDPOINTS
• The investigator made a subjective overall assessment of
the tolerability of the medication, using a verbal rating
scale.
• At the start and at the end of the study blood samples
were taken to evaluate standard hematological and
clinical chemistry safety parameters.
• At the end of therapy blood was taken for an evaluation of
the eltenac serum concentration. The blood samples
were centrifuged and the serum was frozen at −18°C or
below until analysed.
• Adverse events were elicited by nonleading questions to
the patient at every scheduled visit and documented
extensively on a separate form in the case report form.ETHICS
The study was performed according to the Declaration of
Helsinki and following the GCP guidelines of the European
CPMP (Committee on Proprietary Medicinal Products). It
was started only after the relevant national and local
authorities and ethics committees had cleared the study.
In-house and on-site audits were performed.STATISTICAL AND ANALYTICAL PLANS
The confirmatory analysis was based on the main effi-
cacy parameter ‘global pain’, measured on a 10 cm visual
analog scale.
If yi=%-change of VAS measurement relative to baseline(week 1) in week i (i=2,3,4,5), then the main end-point for
each patient was defined as y= y¯=Xiyi, the mean over
E2–E5. In case of missing values for an individual visit the
last observation was carried forward.
It was decided in advance to use the mean over visits
E2–E5 as summary statistic of each individual response to
treatment, because it was assumed that after onset
of treatment a fairly constant treatment effect would be
maintained during this phase.
The primary hypothesis of all pairwise group differences
in the main end-point was tested with simultaneous 90%
confidence limits according to the method of Tukey and
Cramer, including the factor center in a linear model10.
Secondary parameters were analysed in an exploratory
manner.
The confirmatory analysis was based on the intention-to-
treat population which was defined as those patients
having at least two assessments between E2 and E5.
The per-protocol population was defined in a clean
file meeting before breaking the code of the study. It
included all patients who followed the protocol in a reason-
able manner, especially regarding treatment compliance
(amount of gel used), concomitant medication, time
difference between visits and in-/exclusion criteria.
Analysis of safety was performed descriptively for the
safety population (all patients randomized).DETERMINATION OF SAMPLE SIZE
The simultaneous confidence limits for the main end-
point yield a multiple test at an experimentwise error rate of
=0.10, which was thought to be sensible for a pilot study.
A standardized difference of =0.5 was assumed to be a
realistic estimate of efficacy in this study. For feasibility
reasons the number of patients was limited to N=60 per
group. The power 1- was calculated to be 67% for the
comparison of the most effective dose of eltenac gel vs
placebo.ResultsDESCRIPTION OF PATIENT POPULATION
Between June 1994 and January 1995 the four centers
randomized 237 patients (Budapest—center 1: N=100,
Zurich—centre 2: N=9, Prague—centre 3: N=80,
Landshut—centre 4: N=48) which comprise the safety
population. Three patients dropped out immediately after
the admission examination, so that 234 patients were
included in the intention-to-treat (ITT) population. Of theseFor the statistical evaluation pain was transformed to
%-change vs baseline (E1, i.e. time of randomization),
because it was known from previous studies that %-change
to baseline is relatively independent of the baseline pain
values.
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59 patients each to the eltenac 0.3%, eltenac 0.1% and the
placebo groups. Table I shows the reasons for dropouts
and the distribution of patients by group and analysis
population.
Especially due to non-compliance (use of gel below an
daily average of 6 g or above 13.5 g for at least 1 week),
102 of 234 patients had to be excluded from the per-
protocol population. The remaining sample of 132 patients
was not deemed to be representative of the original
population, so no per-protocol analyses were performed.DEMOGRAPHIC AND BASELINE FEATURES
Table II shows baseline characteristics of the intention-
to-treat population. The four groups were well balanced
without statistically significant differences between them.ANALYSIS OF EFFECTIVENESS MEASURES—PRIMARY END-POINT
The analysis of the primary efficacy end-point, the
measurement of global pain on a visual analog scale,
showed a statistically non-significant superiority of eltenac
vs placebo (Table III and Fig. 1). Eltenac gel 0.3% and 1%
were more effective than the 0.1% gel, the advantage of the
highest concentration vs the 0.3% formulation mainly being
a quicker onset of efficacy.Point estimators and confidence limits for the mean pain
reduction (%-change) over visits E2–E5, i.e. the main
statistical end-point of the study, can be seen in Table IV.ANALYSIS OF SECONDARY END-POINTS—LEQUESNE SCORE
Figure 2 shows the results for the ISK score (absolute
values, differences to baseline) for the ITT population. An
analysis of variance (factors: group, center) gave nominally
significant results for visits E3 and FU in the comparisons
of eltenac gel 0.3% and 1.0% vs placebo (P<0.10, cf
‘Determination of sample size’).Table I
Patient distribution
Population details Total Eltenac gel Placebo
gel
1% 0.3% 0.1%
Recruited (safety population) 237 59 60 59 59
Dropout before start of therapy: 3 2 1
non-study-related AE 1 1
lack of time, holidays 2 1 1
Dropout during study, but included in ITT analysis: 10 1 1 5 3
ADR 1 1
lack of efficacy 1 1
non-study-related AE 3 1 1 1
other, non-medical reason 5 4 1
Intention-to-treat population 234 57 59 59 59
Protocol violators 102 27 25 22 28
Per-protocol population 132 30 34 37 31Table II
Baseline characteristics at E0 (mean±s.d.)
Patients’ details Eltenac gel Placebo gel
1% 0.3% 0.1%
Gender (% female) 82 71 80 76
Age (years) 66±8 66±9 67±8 67±7
Height (cm) 163±6 165±8 164±8 165±8
Weight (kg) 76±13 74±12 71±13 74±13
Treated side (% right) 58 53 41 49
Medial JSN (%) 91 93 93 88
Lateral JSN (%) 32 34 27 44
Duration of OA complaints >5 years (%) 49 49 56 63
Analgesic/antiphlogistic drugs during previous year (%) 74/89 69/86 63/85 68/81
Global pain on VAS (0–100 mm) 54.2±24.3 58.8±20.2 57.0±24.7 53.2±23.3
Lequesne score ISK (0–24) 10.7±3.7 10.8±3.8 10.8±3.5 10.7±3.5
Jezek score (0–28) 12.1±4.4 12.4±4.1 12.0±4.2 11.4±4.4ANALYSIS OF SECONDARY END-POINTS—OTHER EFFICACY
END-POINTS
The other secondary end-points—Jezek score, Chatillon
muscle force and dolorimeter measurements, the evalu-
ation of 20 m walking time, the clinical examination results,
the global efficacy evaluation of investigator and patient
and the mean daily intake of the escape analgesic
paracetamol—did not differentiate between treatments. In
most parameters a trend towards superiority of the two
higher eltenac gel concentrations vs placebo was
observed, but did not reach statistical significance.
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Global pain (mm on VAS, mean±s.d.); ITT population
Visit Eltenac gel Placebo gel
1% 0.3% 0.1%
E1 54.53±24.1 58.59±21.5 56.71±23.1 54.05±21.1
E2 47.75±22.4 50.54±21.2 53.15±22.6 49.69±18.0
E3 42.56±23.0 47.05±22.0 48.78±22.1 47.63±17.9
E4 38.40±21.7 42.42±23.1 44.86±22.2 41.19±20.5
E5 35.61±21.3 38.41±23.8 41.90±23.0 38.37±22.6
FU 34.84±24.0 37.14±23.5 39.39±22.1 37.97±22.3Fig. 1. Global pain (VAS). Mean values of %-change to baseline by visit.Table IV
Main end-point
Comparison Difference
between means (%)
90% confidence limits
Lower Upper
Eltenac 0.1% vs placebo −6.16 −20.50 8.17
Eltenac 0.3% vs placebo −10.23 −24.57 4.12
Eltenac 1% vs placebo −10.85 −25.32 3.62EXPLORATORY ANALYSIS OF SUBGROUPS
Based on previous experiences of other authors11–13,
who observed a more marked effect of therapy in patients
with a higher baseline severity of OA, the efficacy of eltenacgel was also analysed in the subgroup of patients with a
Lequesne score of higher than the median, which was 10.5
in this study.
Eltenac gel 1% showed an improved efficacy in these
more severely affected patients (N=111); advantage over
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treatment means), starting at the examination after two
weeks of therapy (Fig. 3). Significant differences were seen
for the eltenac 1% vs placebo comparison at visits E3, E5
and FU (P<0.05).
No such clear-cut baseline dependency was observed in
the other efficacy parameters.
Further subgroup analyses showed that dose response
was considerably more pronounced in male patients than in
female and also in older (≥65 years) than in younger
patients.
As daily gel application by the patients varied consider-
ably between approximately 3 g and 14 g (intended con-
sumption: 9 g), the regression of pain reduction on mean
daily gel dose was calculated. No correlation between
these two variables was found in any of the four study
groups (eltenac gel 1%/0.3%/0.1%/placebo: R 2=0.0092/
0.0042/0.0168/0.0037).Safety
ADVERSE EVENTS
During the study 17 adverse events were observed in 16
of 237 patients. Two reactions each to eltenac 1% and to
placebo were considered to have a possible relationship
to the study medication. This equals an ADR rate of 3.5%
in the respective groups.All four reactions were described as local reddening
and/or itching, which lasted for a period between 1 h and
2 days. In one of the two placebo patients these symptoms
were accompanied by papules at the application area.TOLERABILITY AND LABORATORY
Tolerability was judged to be good or very good in
96–100% of patients, regardless of the treatment group.
The only classification as poor was seen in the placebo
group. Also the safety laboratory evaluation showed no
deviations or patterns suspicious of adverse effects of
eltenac.ELTENAC SERUM CONCENTRATION
In most patients eltenac serum concentrations were
below or around the limit of quantitation (LQ) (5 ng/ml).
When samples with a concentration below LQ were calcu-
lated as LQ, the mean serum concentration in the eltenac
gel 0.1%, 0.3% and 1% group were 5.8, 8.1 and 10.3 ng/ml,
thus showing a dose-dependent increase. No correlation of
eltenac serum concentration with change of global pain
was observed.Fig. 2. Lequesne index (ISK). Mean values of reduction vs baseline by visit. ITT population.Discussion
The aim of this study was to establish the eltenac
concentration with the best benefit–risk ratio in patients
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treated with eltenac gel of three different concentrations
(0.1%, 0.3% and 1%) or with the corresponding placebo
gel. No previous information on the efficacy profile of
eltenac and on the kinetics of the clinical response in this
indication was available. A medium efficacy of the most
active eltenac concentration according to biometrical
standards (standardized difference of 0.5), a quick onset of
efficacy and a maintained effect during the study period
were presumed. As nothing was known about possible
responder populations no according patient pre-selection
was performed.
The graphical depiction of the mean global pain and of
the mean Lequesne score of the intention-to-treat popula-
tion suggested a dose-dependent efficacy; the main differ-
ence between the two highest concentrations was a
quicker onset of efficacy with the highest concentration.
The statistical evaluation, however, did not yield significant
differences between treatment groups.
The efficacy kinetics were different from the expected
course, showing a slower onset of improvement than
anticipated and a practically monotonous decrease of
severity over time in all four groups. The expected stand-
ardized difference of 0.5 was not reached; depending
on efficacy parameter and time of evaluation, the standard-
ized difference ranged only between approximately 0.25
and 0.3. Accordingly the power of the study to verify a
superiority of eltenac vs placebo was only approximately
40–50%, which was lower than anticipated (67%).The visual analog pain scale proved to be less suitable
as a main efficacy parameter than the Lequesne score ISK,
which showed a better selectivity between active drugs and
placebo. The difference observed between eltenac gel 1%
and placebo ranged between 0.5 and 1 ISK-point and must
be considered to be at the border of clinical relevance14.
Daily amount of gel use was not correlated to
clinical efficacy. It is assumed that possibly quite small
quantities of gel, such as single doses of 1 g, are also
sufficient for therapy. Higher doses may result in a thicker
gel layer, but do not lead to the absorption of increased
amounts of drug.
Eltenac serum concentration showed no correlation with
changes in global pain. This supports the view that serum
drug concentrations are of limited value for the assessment
of clinical efficacy of topical NSAIDs and thus cannot
substitute clinical end-points.
Based on published experience with hyaluronic acid and
with eltenac11–13, where a more pronounced efficacy in
patients with a higher baseline severity of knee OA had
been reported, a respective analysis was performed for this
study.
The superiority of eltenac gel 1% over placebo observed
in these more severely affected patients, that is up to 1.6
ISK-points, can be considered clinically relevant14; it is
comparable to that observed after intake of oral NSAIDs.
The reason for this subgroup effect is not known and
must remain speculative at this time. Higher baseline
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thus may make it easier to verify an advantage statistically.
Possibly also patients with more severe OA have a better
knowledge of their disease, making them, because more
experienced, a particularly useful study population. This
view is supported by the observation that older patients
(>65 years) showed a more homogeneous development of
pain over time. In this population also a clear dose–
response relationship was observed, which was missing in
the patient sample below 65 years of age.
This pilot study did not provide confirmatory proof of an
efficacy of eltenac gel in patients with pain due to knee OA.
It provides hints on the most effective concentration of
eltenac in a gel formulation (1%) and also some insight into
methodological problems that have to be observed for the
planning of confirmatory studies.
In this study, eltenac showed its efficacy best in patients
with at least moderate to severe knee OA. This efficacy
developed within the first 2 weeks of therapy and was
maintained until the end of treatment. The Lequesne score
was more sensitive in the detection of drug effects than the
visual analog pain scale. Although its validity has been
questioned, among others by Stucki et al.15,16 the
Lequesne score has been recommended as an outcome
parameter for studies in OA by the OARS, GREES and
OMERACT17–19.
One encouraging point for future developments in this
therapeutic field is the observation that dose-finding studies
seem to be feasible even with topical NSAIDs.Acknowledgments
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